ALT vs DBVT vs HALO vs NVO vs MRK

For growth investors, Altimmune, Inc.

(ALT) is the stronger pick with 105. 0% revenue growth year-over-year, versus 1. 2% for Merck & Co. , Inc. (MRK). Novo Nordisk A/S (NVO) offers the better valuation at 12. 7x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate Altimmune, Inc. (ALT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

7x versus Halozyme Therapeutics, Inc. at 25. 0x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novo Nordisk A/S wins at 0. 10x versus Merck & Co. , Inc. 's 1. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +69. 5%, compared to -76. 4% for Altimmune, Inc. (ALT). Over 10 years, the gap is even starker: ALT returned +1213% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 45β versus Novo Nordisk A/S's 1. 52β — meaning NVO is approximately 235% more volatile than MRK relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Altimmune, Inc.

(ALT) is pulling ahead at 105. 0% versus 1. 2% for Merck & Co. , Inc. (MRK). On earnings-per-share growth, the picture is similar: Altimmune, Inc. grew EPS 25. 4% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus -2148. 6% for Altimmune, Inc. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -2304. 6% for ALT. At the gross margin level — before operating expenses — NVO leads at 81. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novo Nordisk A/S (NVO) is the more undervalued stock at a PEG of 0. 10x versus Merck & Co. , Inc. 's 1. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2. 1x forward P/E versus 21. 7x for Merck & Co. , Inc. — 19. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALT: 264. 1% to $11. 25.

In this comparison, NVO (4.

0% yield), MRK (2. 9% yield) pay a dividend. ALT, DBVT, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 2. 9% yield, +164. 7% 10Y return). Both have compounded well over 10 years (MRK: +164. 7%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALT is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; HALO is a small-cap high-growth stock; NVO is a large-cap deep-value stock; MRK is a large-cap deep-value stock. NVO, MRK pay a dividend while ALT, DBVT, HALO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.